{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T09:35:47Z","timestamp":1781602547486,"version":"3.54.5"},"reference-count":51,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2023,2,21]],"date-time":"2023-02-21T00:00:00Z","timestamp":1676937600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Antibiotics"],"abstract":"<jats:p>There has been widespread implementation of pharmacogenomic testing to inform drug prescribing in medical specialties such as oncology and cardiology. Progress in using pharmacogenomic tests when prescribing antimicrobials has been more limited, though a relatively large number of pharmacogenomic studies on aspects such as idiosyncratic adverse drug reactions have now been performed for this drug class. Currently, there are recommendations in place from either National Regulatory Agencies and\/or specialist Pharmacogenomics Advisory Groups concerning genotyping for specific variants in MT-RNR1 and CYP2C19 before prescribing aminoglycosides and voriconazole, respectively. Numerous additional pharmacogenomic associations have been reported concerning antimicrobial-related idiosyncratic adverse drug reactions, particularly involving specific HLA alleles, but, to date, the cost-effectiveness of genotyping prior to prescription has not been confirmed. Polygenic risk score determination has been investigated to a more limited extent but currently suffers from important limitations. Despite limited progress to date, the future widespread adoption of preemptive genotyping and genome sequencing may provide pharmacogenomic data to prescribers that can be used to inform prescribing and increase the safe use of antimicrobials.<\/jats:p>","DOI":"10.3390\/antibiotics12030425","type":"journal-article","created":{"date-parts":[[2023,2,21]],"date-time":"2023-02-21T02:07:44Z","timestamp":1676945264000},"page":"425","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Relevance of Pharmacogenomics to the Safe Use of Antimicrobials"],"prefix":"10.3390","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7321-0629","authenticated-orcid":false,"given":"Ann K.","family":"Daly","sequence":"first","affiliation":[{"name":"Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne NE2 4HH, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,2,21]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/j.cll.2022.09.012","article-title":"Precision Medicine Using Pharmacogenomic Panel-Testing: Current Status and Future Perspectives","volume":"42","author":"Guchelaar","year":"2022","journal-title":"Clin. Lab. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"145","DOI":"10.2217\/pgs-2017-0123","article-title":"Precision medicine for HIV: Where are we?","volume":"19","author":"Cusato","year":"2018","journal-title":"Pharmacogenomics"},{"key":"ref_3","unstructured":"Brunton, L., and Knollmann, B. (2022). Goodman and Gilman\u2019s the Pharmacological Basis of Therapeutics, McGraw-Hill Education. [14th ed.]."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/S0140-6736(18)32218-9","article-title":"Antibiotic allergy","volume":"393","author":"Blumenthal","year":"2019","journal-title":"Lancet"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1124\/pr.113.007450","article-title":"Idiosyncratic adverse drug reactions: Current concepts","volume":"65","author":"Uetrecht","year":"2013","journal-title":"Pharmacol. Rev."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1111\/cts.13424","article-title":"Genetics of drug-induced liver injury: Current knowledge and future prospects","volume":"16","author":"Daly","year":"2022","journal-title":"Clin. Transl. Sci."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1053\/j.gastro.2011.04.001","article-title":"Susceptibility to Amoxicillin-Clavulanate-Induced Liver Injury Is Influenced by Multiple HLA Class I and II Alleles","volume":"141","author":"Lucena","year":"2011","journal-title":"Gastroenterology"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1053\/j.gastro.2016.12.016","article-title":"Association of Liver Injury From Specific Drugs, or Groups of Drugs, With Polymorphisms in HLA and Other Genes in a Genome-Wide Association Study","volume":"152","author":"Nicoletti","year":"2017","journal-title":"Gastroenterology"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1056\/NEJMoa1213096","article-title":"HLA-B*13:01 and the dapsone hypersensitivity syndrome","volume":"369","author":"Zhang","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1002\/hep.31258","article-title":"Human Leukocyte Antigen B*14:01 and B*35:01 Are Associated With Trimethoprim-Sulfamethoxazole Induced Liver Injury","volume":"73","author":"Li","year":"2021","journal-title":"Hepatology"},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Nicoletti, P., Dellinger, A., Li, Y.J., Barnhart, H.X., Chalasani, N., Fontana, R.J., Odin, J.A., Serrano, J., Stolz, A., and Etheridge, A.S. (2022). Identification of Reduced ERAP2 Expression and a Novel HLA Allele as Components of a Risk Score for Susceptibility to Liver Injury Due to Amoxicillin-Clavulanate. Gastroenterology, in press.","DOI":"10.1053\/j.gastro.2022.11.036"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.jhep.2017.03.010","article-title":"Minocycline hepatotoxicity: Clinical characterization and identification of HLA-B\u221735:02 as a risk factor","volume":"67","author":"Urban","year":"2017","journal-title":"J. Hepatol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1016\/j.ajhg.2020.08.008","article-title":"Genome-wide Study Identifies Association between HLA-B(\u2217)55:01 and Self-Reported Penicillin Allergy","volume":"107","author":"Krebs","year":"2020","journal-title":"Am. J. Hum. Genet."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1038\/ng.379","article-title":"HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin","volume":"41","author":"Daly","year":"2009","journal-title":"Nat. Genet."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"90","DOI":"10.3389\/fphar.2017.00090","article-title":"HLA-B*57 Allele Is Associated with Concomitant Anti-tuberculosis and Antiretroviral Drugs Induced Liver Toxicity in Ethiopians","volume":"8","author":"Petros","year":"2017","journal-title":"Front. Pharmacol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1002\/cpt.1375","article-title":"Drug-Induced Liver Injury due to Flucloxacillin: Relevance of Multiple Human Leukocyte Antigen Alleles","volume":"106","author":"Nicoletti","year":"2019","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1016\/j.jaci.2020.10.004","article-title":"Beta-lactam-induced immediate hypersensitivity reactions: A genome-wide association study of a deeply phenotyped cohort","volume":"147","author":"Nicoletti","year":"2021","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.jhep.2022.09.010","article-title":"Clinical features, outcomes, and HLA risk factors associated with nitrofurantoin-induced liver injury","volume":"78","author":"Chalasani","year":"2023","journal-title":"J. Hepatol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1111\/all.15147","article-title":"Next-generation sequencing and genotype association studies reveal the association of HLA-DRB3*02:02 with delayed hypersensitivity to penicillins","volume":"77","author":"Romano","year":"2022","journal-title":"Allergy"},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Jee, A., Sernoskie, S.C., and Uetrecht, J. (2021). Idiosyncratic Drug-Induced Liver Injury: Mechanistic and Clinical Challenges. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22062954"},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Manson, L.E.N., van den Hout, W.B., and Guchelaar, H.J. (2021). Genotyping for HLA Risk Alleles to Prevent Drug Hypersensitivity Reactions: Impact Analysis. Pharmaceuticals, 15.","DOI":"10.3390\/ph15010004"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"483","DOI":"10.5588\/ijtld.22.0188","article-title":"Clinical standards for the dosing and management of TB drugs","volume":"26","author":"Alffenaar","year":"2022","journal-title":"Int. J. Tuberc. Lung Dis."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1164\/rccm.200510-1666ST","article-title":"An official ATS statement: Hepatotoxicity of antituberculosis therapy","volume":"174","author":"Saukkonen","year":"2006","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.jceh.2012.12.001","article-title":"Hepatotoxicity Related to Anti-tuberculosis Drugs: Mechanisms and Management","volume":"3","author":"Ramappa","year":"2013","journal-title":"J. Clin. Exp. Hepatol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1164\/arrd.1972.106.3.357","article-title":"Isoniazid-associated hepatitis. Report of an outbreak","volume":"106","author":"Garibaldi","year":"1972","journal-title":"Am. Rev. Respir. disease"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1038\/nrgastro.2010.134","article-title":"Hepatotoxic effects of therapies for tuberculosis","volume":"7","author":"Senousy","year":"2010","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1080\/17425255.2021.1840551","article-title":"Arylamine N-acetyltransferase acetylation polymorphisms: Paradigm for pharmacogenomic-guided therapy- a focused review","volume":"17","author":"Hein","year":"2021","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"293","DOI":"10.5588\/ijtld.18.0324","article-title":"NAT2 variants and toxicity related to anti-tuberculosis agents: A systematic review and meta-analysis","volume":"23","author":"Richardson","year":"2019","journal-title":"Int. J. Tuberc. Lung Dis."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"e02692-18","DOI":"10.1128\/AAC.02692-18","article-title":"Genomewide Association Study Confirming the Association of NAT2 with Susceptibility to Antituberculosis Drug-Induced Liver Injury in Thai Patients","volume":"63","author":"Suvichapanich","year":"2019","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1002\/cpt.2100","article-title":"Genetic Risk Factors in Drug-Induced Liver Injury Due to Isoniazid-Containing Antituberculosis Drug Regimens","volume":"109","author":"Nicoletti","year":"2021","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"652704","DOI":"10.3389\/fgene.2021.652704","article-title":"Functional Characterization of the Effects of N-acetyltransferase 2 Alleles on N-acetylation of Eight Drugs and Worldwide Distribution of Substrate-Specific Diversity","volume":"12","author":"Fukunaga","year":"2021","journal-title":"Front. Genet."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1093\/toxsci\/kfh232","article-title":"Hepatic gene expression and lipid homeostasis in C57BL\/6 mice exposed to hydrazine or acetylhydrazine","volume":"82","author":"Richards","year":"2004","journal-title":"Toxicol. Sci."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1007\/s00228-012-1429-9","article-title":"NAT2 genotype guided regimen reduces isoniazid-induced liver injury and early treatment failure in the 6-month four-drug standard treatment of tuberculosis: A randomized controlled trial for pharmacogenetics-based therapy","volume":"69","author":"Azuma","year":"2013","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1044\/2021_AJA-21-00006","article-title":"Mechanisms of Aminoglycoside- and Cisplatin-Induced Ototoxicity","volume":"30","author":"Steyger","year":"2021","journal-title":"Am. J. Audiol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1007\/PL00000673","article-title":"Mitochondrial defects and hearing loss","volume":"57","author":"Hutchin","year":"2000","journal-title":"Cell Mol. Life Sci."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1001\/jamapediatrics.2022.0187","article-title":"Rapid Point-of-Care Genotyping to Avoid Aminoglycoside-Induced Ototoxicity in Neonatal Intensive Care","volume":"176","author":"McDermott","year":"2022","journal-title":"JAMA Pediatr."},{"key":"ref_37","unstructured":"Medicines and Healthcare Products Regulatory Agency (2021). Aminoglycosides (Gentamicin, Amikacin, Tobramycin, and Neomycin): Increased Risk of Deafness in Patients with Mitochondrial Mutations."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1002\/cpt.2309","article-title":"Clinical Pharmacogenetics Implementation Consortium Guideline for the Use of Aminoglycosides Based on MT-RNR1 Genotype","volume":"111","author":"McDermott","year":"2022","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"a033548","DOI":"10.1101\/cshperspect.a033548","article-title":"Aminoglycoside- and Cisplatin-Induced Ototoxicity: Mechanisms and Otoprotective Strategies","volume":"9","author":"Kros","year":"2019","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"e00931","DOI":"10.1002\/prp2.931","article-title":"Healthcare costs and mortality associated with serious fluoroquinolone-related adverse reactions","volume":"10","author":"Kuula","year":"2022","journal-title":"Pharmacol. Res. Perspect."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1080\/14740338.2022.2147924","article-title":"Fluoroquinolones: Old drugs, putative new toxicities","volume":"21","author":"Bove","year":"2022","journal-title":"Expert Opin. Drug Saf."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1086\/525258","article-title":"Treatment of aspergillosis: Clinical practice guidelines of the Infectious Diseases Society of America","volume":"46","author":"Walsh","year":"2008","journal-title":"Clin. Infect. Dis."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1002\/cpt.1973","article-title":"PharmVar GeneFocus: CYP2C19","volume":"109","author":"Botton","year":"2021","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1002\/cncr.22568","article-title":"Monitoring plasma voriconazole levels may be necessary to avoid subtherapeutic levels in hematopoietic stem cell transplant recipients","volume":"109","author":"Trifilio","year":"2007","journal-title":"Cancer"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1002\/cpt.583","article-title":"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP2C19 and Voriconazole Therapy","volume":"102","author":"Moriyama","year":"2017","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"3525","DOI":"10.1093\/hmg\/ddp295","article-title":"Harnessing the information contained within genome-wide association studies to improve individual prediction of complex disease risk","volume":"18","author":"Evans","year":"2009","journal-title":"Hum. Mol. Genet."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1000667","DOI":"10.3389\/fgene.2022.1000667","article-title":"Polygenic risk scores: An overview from bench to bedside for personalised medicine","volume":"13","author":"Cross","year":"2022","journal-title":"Front. Genet."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1038\/s41591-020-1023-0","article-title":"Polygenic architecture informs potential vulnerability to drug-induced liver injury","volume":"26","author":"Koido","year":"2020","journal-title":"Nat. Med."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1053\/j.gastro.2019.01.034","article-title":"A Missense Variant in PTPN22 is a Risk Factor for Drug-induced Liver Injury","volume":"156","author":"Cirulli","year":"2019","journal-title":"Gastroenterology"},{"key":"ref_50","first-page":"303","article-title":"Point of care CYP2C19 genotyping after percutaneous coronary intervention","volume":"22","author":"Baudhuin","year":"2022","journal-title":"Pharm. J."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1016\/j.drudis.2021.04.015","article-title":"Towards population-specific pharmacogenomics in the era of next-generation sequencing","volume":"26","author":"Ji","year":"2021","journal-title":"Drug Discov. Today"}],"container-title":["Antibiotics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2079-6382\/12\/3\/425\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T18:37:46Z","timestamp":1760121466000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2079-6382\/12\/3\/425"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,21]]},"references-count":51,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2023,3]]}},"alternative-id":["antibiotics12030425"],"URL":"https:\/\/doi.org\/10.3390\/antibiotics12030425","relation":{},"ISSN":["2079-6382"],"issn-type":[{"value":"2079-6382","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,21]]}}}